Cantor Fitzgerald Reaffirms “Neutral” Rating for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ:AMED)‘s stock had its “neutral” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They presently have a $101.00 price objective on the health services provider’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 3.06% from the company’s previous close.

A number of other research analysts have also recently commented on the company. William Blair cut Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $100.67.

Amedisys Price Performance

Shares of AMED stock traded up $0.42 during trading hours on Thursday, reaching $98.00. The company’s stock had a trading volume of 23,787 shares, compared to its average volume of 312,624. The firm’s 50 day simple moving average is $94.76 and its 200-day simple moving average is $93.76. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of -153.12, a PEG ratio of 2.40 and a beta of 0.79. Amedisys has a fifty-two week low of $89.55 and a fifty-two week high of $98.46. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.00 EPS. Sell-side analysts forecast that Amedisys will post 4.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AMED. Water Island Capital LLC raised its position in Amedisys by 185.0% during the 4th quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock worth $67,559,000 after purchasing an additional 461,368 shares during the last quarter. Norges Bank bought a new position in Amedisys during the 4th quarter worth $34,032,000. Segantii Capital Management Ltd bought a new position in Amedisys during the 4th quarter worth $32,776,000. Calamos Advisors LLC bought a new position in Amedisys during the 4th quarter worth $23,015,000. Finally, Alpine Associates Management Inc. raised its position in Amedisys by 23.0% during the 4th quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock worth $120,830,000 after purchasing an additional 237,600 shares during the last quarter. 94.36% of the stock is owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.